Skip to content
MarketScale
‹ Back to IndustriesSciences

Why We Show Up for Care

Episode 4 of The Future of Patient Monitoring takes a step back from infrastructure and innovation to explore something deeper: the people behind the technology—and what they’ve learned through years of building smarter systems. Part of the Health and Life Sciences at the Edge podcast series, this conversation is led by Intel’s Kaeli Tully,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Michelle Dawn Mooney · Clinician WorkflowHealthcare DataHealthcare InnovationHospital Infrastructure
Share

Key takeaways

01

Episode 4 of The Future of Patient Monitoring takes a step back from infrastructure and innovation to explore something deeper: the people behind the technology—and what they’ve learned through years of building smarter systems.

02

Part of the Health and Life Sciences at the Edge podcast series, this conversation is led by Intel’s Kaeli Tully,…

Episode 4 of The Future of Patient Monitoring takes a step back from infrastructure and innovation to explore something deeper: the people behind the technology—and what they’ve learned through years of building smarter systems. Part of the Health and Life Sciences at the Edge podcast series, this conversation is led by Intel’s Kaeli Tully, who’s joined by Dr. Sanjay Subramanian, Critical Care Physician and CEO/Founder of Omnicure, Bikram Day, Director of Informatics at Medical Informatics Corp., and Andrew Lamkin, Health and Life Sciences Solutions Architect at Intel.

Each guest brings a unique origin story to the space. “As they say, this is that intersection of what’s great to do and what’s wanted by society,” says Day, who’s been connecting devices since childhood. Subramanian emphasizes the clinician’s lens, noting, “There’s always a need to make technology work best for clinicians… not all have the bandwidth or training to take that leap, but it’s impactful if you do.” Lamkin adds, “Healthcare is so much more challenging in so many ways than aerospace. It’s such a tough environment to introduce technology into thoughtfully.”

The episode also dives into standout projects, like the National Emergency Critical Care Network (NET-CCN), which connected patients to critical care physicians nationwide during COVID-19 using only smartphones. From early EMR integrations to scalable AI applications, each guest shares what they’ve learned about moving from data to decisions.

Interoperability, modularity, infrastructure planning—all those things pay long-term dividends,” says Lamkin. Meanwhile, Day looks to what’s next: “If we can store and correlate data, those insights become valuable. AI can literally build the chain of events and causality.”

Ultimately, the conversation is a powerful reminder that healthcare innovation is a human journey—and the smartest systems are the ones designed to support real people, every step of the way.

Connect with the thought leaders driving this discussion:

Subscribe to this channel on Apple Podcasts and Spotify to hear more from the Intel Internet of Things Group.

About the author

MD

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

MD
Michelle Dawn Mooney

Michelle Dawn Mooney is a media professional and host known for her work in broadcast journalism and B2B content.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512